66 results about "Ovarian Insufficiency" patented technology

Provided is a drug for treating ovarian insufficiency. In particular, the present invention relates to the use of annexins in the preparation of a pharmaceutical composition used for preventing and / or treating ovarian insufficiency.

The invention provides a preparation method and application of an engineered exosome derived from placenta mesenchymal stem cells, and belongs to the field of biological medicine. According to the invention, the placenta mesenchymal stem cells transfected with the miRNA virus vector are constructed, the engineered exosome is prepared in a culture system under an anoxic condition and stimulated by estrogen, and the invention also provides application of the placenta mesenchymal stem cells and the exosome in preparation of medicines for treating ovarian insufficiency, female climacteric syndrome and the like. The miRNA transfected placenta mesenchymal stem cells and exosomes provided by the invention have good effects in the aspects of treating ovarian insufficiency, female climacteric syndrome and the like.

The invention discloses a method and a device for predicting and evaluating early-stage ovarian insufficiency. The method comprises the following steps: acquiring clinical and image parameters of a patient; the ovarian image data of the patient is input into an ovarian matrix extraction network model, morphological texture features are obtained, and the ovarian matrix extraction network model comprises an MRI sequence input layer, a slics scribing layer, a matrix feature fusion layer and a feedback network composed of a plurality of convolution layers and fusion layers; the morphological texture features comprise a gray-level co-occurrence matrix, a gray-level run-length matrix, a gray-level dependent matrix and a neighborhood gray-level difference matrix; inputting the clinical parameter data and the morphological texture features into an early-stage ovarian insufficiency prediction model, and outputting a prediction result of the early-stage ovarian insufficiency; the early ovarian insufficiency prediction model comprises a plurality of internal residual networks, an EMP model, an LMP model and a VGG-16 network. Through the ovarian matrix extraction network model and the early ovarian insufficiency prediction model, the early ovarian insufficiency prediction precision is further improved.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a medicine for treating premature ovarian insufficiency and application, the medicine comprises a modified kidney-tonifying pill, and the modified kidney-tonifying pill is prepared from radix rehmanniae preparata, Chinese yam, poria cocos, wine-prepared fructus corni, angelica sinensis, fructus lycii, salted eucommia ulmoides, salted semen cuscutae, raspberry and mulberry according to the mass ratio of 2: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1. Research finds that when a female progestational hormone sequential therapy is combined with the modified kidney-invigorating pill to treat a kidney deficiency type POI patient, clinical symptoms in multiple aspects of menstrual cycle, menstrual period, menstrual dose, soreness and weakness of waist and knees, dizziness and tinnitus, hectic fever and night sweat, sexual apathy and frequent urination at night can be remarkably improved, the serum FSH and LH levels are reduced, the E2 level is improved, and the traditional Chinese medicine composition is worthy of clinical popularization and has a wide application prospect. The theoretical basis and clinical guidance are provided for treating the kidney deficiency type POI through traditional Chinese medicine.

The invention belongs to the field of traditional Chinese medicine, and particularly relates to Kunxinning and a preparation method and application thereof. The effective components of the Kunxingning disclosed by the invention are artemisinin and artemisinin. Animal experiments prove that kunxingning can improve the early-onset ovarian insufficiency toxicity state of SD rats caused by tripterygium glycosides, reduce ovarian granular cell apoptosis, improve the ovarian pathological state, promote follicular development, restore the serum sex hormone level to be normal to a certain extent, improve the state of proportion imbalance of Th17 / Treg immune cells, and improve the early-onset ovarian insufficiency toxicity of the SD rats. And the mood cycle of the rats is recovered to a certain extent. Meanwhile, the physiological activity of the tripterygium glycosides composition obtained by compounding the kunxingning and the TG is equivalent to that of the TG.

The invention discloses an oral drug delivery system with a double-emulsion structure and application of the oral drug delivery system in preparation of drugs for treating premature ovarian insufficiency, and belongs to the technical field of biological medicines. The oral drug delivery system comprises droplet particles formed by wrapping an MSCs conditioned culture medium with an oil-phase solvent, and exosomes uniformly distributed on the outer surfaces of the droplet particles, so that a double-emulsion structure is formed. Water-soluble MSC-CM is wrapped by a water-in-oil-in-water method to form a double-emulsion structure, so that water-soluble protein enters a human body to be absorbed in an oral manner. The MSC-CM composite has good structural stability and viscoelasticity, the particle size range is about 10-50 microns, contact with intestinal epithelial cells can be increased, meanwhile, the skeleton of the intestinal epithelial cells can be changed, expression of tight junction protein of the intestinal epithelial cells can be lowered, tight junction barriers of the intestinal epithelial cells can be opened, and therefore the bioavailability of MSC-CM is improved, and the MSC-CM composite has a good application prospect. The effect of treating the POI is achieved.

The invention provides a premature ovarian insufficiency (POI) animal model and a construction method thereof, and particularly, the method utilizes chronic unpredictable pressure stress to construct different pathological stage models of mouse POI, and comprises the following steps: screening experimental animals with normal ovarian functions, adaptively feeding, applying various pressure stresses to the experimental animals, and obtaining the POI animal model. The POI model has a compensatory period, and is more in line with the clinical pathological process of patients suffering from premature ovarian insufficiency caused by common pressure in modern society.

Provided is use of thyroxine and a thyroxine receptor inhibitor in preparing drugs for regulating primordial follicle activation, belonging to the technical field of biology. It has been discovered that the thyroxine can promote primordial follicle activation, and the thyroxine receptor inhibitor inhibits primordial follicle activation, so that they can be used as drugs for regulating primordial follicle activation in patients with premature ovarian insufficiency.

The invention belongs to the technical field of medicines, and particularly relates to application of kaifeng essence to preparation of a medicine for treating premature ovarian insufficiency. The kaifeng essence has high total effective rate for adjuvant therapy of premature ovarian insufficiency and obvious clinical curative effect, and is a potential effective therapeutic drug.

The invention provides a diagnostic application of NDUFS5 in premature ovarian insufficiency disease, the NDUFS5 peripheral blood expression level (mRNA) is detected to have a significant difference between POI and a control group, the difference is verified by qPCR in an independent queue, and the result shows that the expression of the NDUFS5 gene in the premature ovarian insufficiency group is significantly reduced compared with the control group, and the NDUFS5 gene has a significant effect on the premature ovarian insufficiency disease. The trend is consistent with that of transcriptome sequencing, and meanwhile, training and verification data are combined to prove that the NDUFS5 can be applied to distinguishing normal ovarian functions and ovarian insufficiency. The kit can be used for diagnosis of premature ovarian insufficiency (premature ovarian failure and ovarian aging), solves the clinical dilemma that diagnosis is delayed by means of existing means for POI diseases in the prior art, enables high-risk groups to be capable of early prediction or early warning, and avoids the risk that irreversible fertility is lost in advance due to the fact that the optimal period of early intervention is missed.

Provided are an ovary-targeting polypeptide, a derivative of the polypeptide, and the use of the polypeptide in the preparation of a drug or reagent for treating ovarian related reproductive diseases and preventing and treating the in-vivo or in-vitro aging of oocytes. The diseases comprise menstrual cycle disorder, polycystic ovary syndrome, androgenic phenotype, hair loss, abnormal metabolism, ovarian insufficiency, premature ovarian failure, ovulation failure, abnormal glucose metabolism, and abnormal lipid metabolism, preferably, hyperglycemia and insulin resistance. In addition, the polypeptide is expected to prolong the preservation time and improve the preservation quality of oocytes or fertilized eggs in the field of assisted reproduction.

The invention is in the field of medical formulations. Specifically, the invention provides a pharmaceutical composition, the pharmaceutical composition comprises in-vitro regenerated platelets and / or a culture supernatant of the in-vitro regenerated platelets, and the in-vitro regenerated platelets have the following characteristics: the FGF level is significantly increased and / or the VEGF level is significantly increased; the pharmaceutical composition is used for promoting ovarian regeneration, improving ovarian endocrine function, improving ovarian reserve function, and / or improving mouse fertility outcome.

The invention discloses a compound traditional Chinese medicine preparation for treating postmenopausal osteoporosis, osteoarthritis and / or premature ovarian insufficiency as well as a preparation method and application of the compound traditional Chinese medicine preparation, and belongs to the technical field of traditional Chinese medicines. The compound traditional Chinese medicine preparation is prepared from the following components: 10 to 30 g of radix rehmanniae preparata, 10 to 30 g of radix angelicae sinensis, 8 to 15 g of rhizoma chuanxiong, 8 to 15 g of radix paeoniae alba, 10 to 30 g of radix codonopsis, 8 to 15 g of rhizoma atractylodis macrocephalae, 10 to 30 g of poria cocos, 5 to 10 g of liquorice root, 10 to 30 g of radix dipsaci, 8 to 15 g of radix achyranthis bidentatae, 8 to 15 g of fructus chaenomelis lagenariae, the compound traditional Chinese medicine preparation provided by the invention realizes effective treatment on osteoporosis, osteoarthritis and early-onset ovarian insufficiency, overcomes various defects of an existing treatment method, remarkably improves the treatment effect, reduces the side effects of medicines, and brings a new treatment choice for patients. And a new thought and a new method are expected to be provided for solving the treatment problem of the three diseases.

The invention relates to application of kaempferol in preparation of drugs, food or health care products for preventing or treating premature ovarian insufficiency diseases caused by chemotherapy drugs. Experiments prove that the estrus cycle disorder of mice exposed to chemotherapeutics can be improved by the administration of the kaempferol; the kaempferol administration can improve the ovarian organ coefficient of the mouse exposed by the chemotherapeutic drug; the administration of kaempferol can effectively improve mouse ovarian hormone level disorder caused by exposure of chemotherapeutic drugs; the kaempferol can increase the number of effect follicles at all levels, reduce the number of atresia follicles and increase the total number of follicles. Experiments prove that kaempferol has a potential value in early-onset ovarian insufficiency caused by chemotherapeutic drugs, and a new method and a new idea are provided for clinical treatment of POI. The method has good popularization and application values.

A pharmaceutical composition and method for preventing or treating ovarian insufficiency includes umbilical cord-derived adherent stem cells. The umbilical cord-derived adherent stem cells increase the number and proportion of follicles or primordial follicles, induce superovulation of oocytes, or promote the development of fertilized embryos. Accordingly, the composition and the method are usefully employed in the prevention or treatment of ovarian insufficiency, including premature menopause or infertility.

This invention relates to the pharmaceutical field, specifically disclosing a pharmaceutical composition and its application. The composition comprises sibifluin, uridine, and adenosine, wherein the mass ratio of sibifluin:uridine:adenosine is 6.0-11.5:0.8-1.4:1.0. This pharmaceutical composition exhibits good safety and anti-inflammatory effects, demonstrates good efficacy in the treatment of phenylketonuria, and also shows good preventative and / or therapeutic effects against ovarian insufficiency.

The invention relates to the technical field of biological medicines, discloses application of a three-seed homing decoction in treatment of premature ovarian insufficiency and a premature ovarian insufficiency biomarker, and researches and develops a traditional Chinese medicine compound, namely the three-seed homing decoction, which has a remarkable effect on treatment of the premature ovarian insufficiency. Experiments prove that the traditional Chinese medicine composition has the effect of improving the ovarian function of model group rats, and a new treatment medicine is provided for treating premature ovarian insufficiency. The specific target spot of the three-seed homing decoction for treating the premature ovarian insufficiency is further analyzed and defined through network pharmacology, and key genes of the premature ovarian insufficiency are further analyzed and found through combination of proteomics and genomics. The target spots and the key genes have a plurality of application prospects for the subsequent research on the individualized drug effect of the three-seed homing decoction, the preparation or development of diagnostic kits for ovarian insufficiency, the screening of drugs for treating premature ovarian insufficiency and the like.

The invention discloses a traditional Chinese medicine composition for improving related symptoms of ovarian insufficiency and application of the traditional Chinese medicine composition, and belongs to the field of traditional Chinese medicines. The method mainly comprises the following steps: selecting 6-15 parts by weight of artemisia apiacea, 6-12 parts by weight of scutellaria baicalensis, 9-18 parts by weight of morinda officinalis, 15-30 parts by weight of light wheat, 12-24 parts by weight of prepared rehmannia root, 9-18 parts by weight of lily, 3-9 parts by weight of prepared common monkshood daughter root and 15-30 parts by weight of calcined oyster shell, cleaning the raw material medicines to remove non-medicinal parts and impurities, properly crushing the calcined oyster shell to facilitate dissolution of effective components, and drying to obtain the traditional Chinese medicine composition. Soaking the cooked radix aconiti lateralis praeparata slices in saline water, and cooking to reduce the toxicity for later use; through scientific compatibility of traditional Chinese medicines such as artemisia apiacea, scutellaria baicalensis and morinda officinalis, and by following the treatment method of clearing the upper part and warming the lower part and traffic heart and kidney, comprehensive intervention is realized, so that vasomotor symptoms such as hectic fever, night sweat and the like can be remarkably improved, sleep disorders such as insomnia, upset and the like can be relieved, osteoporosis can be prevented and improved through the effects of tonifying kidney and strengthening bone, and meanwhile, the immune imbalance state can be regulated.

The application discloses a method for treating premature ovarian insufficiency by using a double-targeting biomimetic nanoparticle based on a wolfberry-derived extracellular vesicle, relates to the technical field of premature ovarian insufficiency, and obtains wolfberry-derived extracellular vesicles, uses the wolfberry-derived extracellular vesicles as a nano delivery carrier, and realizes the treatment effect on the damage related to chemotherapy-induced premature ovarian insufficiency by using active ingredients carried by the wolfberry-derived extracellular vesicles; the wolfberry-derived extracellular vesicles are coated by using homologous ovarian granulosa cell membranes, and a GCM-LBEVs biomimetic nanoparticle vesicle with granulosa cell recognition ability is constructed. The application realizes the accurate delivery of ovarian granulosa cells and mitochondria by constructing a TPP-GCM-LBEVs double-targeting biomimetic nano system, improves the quality of oocytes, ovarian function and fertility, and provides a new nano strategy for the treatment of POI and mitochondrial-related reproductive disorders.

The invention relates to a traditional Chinese medicine composition and a preparation method and application thereof, and belongs to the technical field of biological medicine. The traditional Chinese medicine composition is prepared from thirty traditional Chinese medicine raw materials such as bull penis, cortex cinnamomi and alfalfa seeds and refined honey. The traditional Chinese medicine raw materials are crushed and mixed and then are prepared into honeyed boluses with the refined honey to obtain the traditional Chinese medicine composition. The traditional Chinese medicine composition disclosed by the invention has the effects of warming and nourishing brain and kidney, and benefiting heart and replenishing essence, and can be used for effectively treating impotence, depression, spermatorrhea, premature ejaculation, body deficiency, emaciation, neurasthenia, premature ovarian insufficiency, ovarian reserve hypofunction, climacteric syndrome, infertility and / or infertility. The dracocephalum moldavica, the anchusa, the chicory and the hawthorn are further added, so that the efficacy of treating the impotence can be improved, and the effect of treating the hyperlipidemia is achieved.

The invention relates to a traditional Chinese medicine effective component screening method based on a chemical fingerprint spectrum and multi-omics combined analysis. The method comprises the following steps: preparing a semen cuscutae-fructus lycii medicine pair extract and establishing a UPLC-Q-TOF-MS / MS chemical fingerprint spectrum; detecting the levels of estradiol, luteinizing hormone, anti-mullerian hormone and follicle-stimulating hormone in the premature ovarian insufficiency animal model; screening characteristic components related to the drug effect through multivariate statistical analysis; performing transcriptome sequencing on the ovarian tissue, and combining GO / KEGG analysis to determine a key pathway; integrating database prediction targets and differential genes, screening hub genes and constructing a protein interaction network; and finally verifying the binding activity of the candidate component and the core target protein through molecular docking and molecular dynamics experiments. According to the invention, systematic screening and action mechanism analysis of drug effect related components are realized, and a new technical approach is provided for mass marker determination and estrogen simulating action research of the dodder-wolfberry drug pair.

The application provides application of a hydrogen sulfide donor SPRC in improving early-onset ovarian dysfunction caused by a chemotherapy drug, and relates to the technical field of biomedicine, and the technical key points are as follows: the application provides application of the hydrogen sulfide donor SPRC in preparing a drug for improving early-onset ovarian dysfunction. The present application aims at the technical problems of early-onset ovarian dysfunction causing the decline of female ovarian function and reproductive capacity, including the decline of ovarian index, the reduction of the number of follicles at all levels, and the significant increase of the number of apoptotic cells in ovarian tissue. The specific verification experiments prove that supplementing the hydrogen sulfide donor SPRC in a mouse model of early-onset ovarian dysfunction can improve the body weight and ovarian index of the mouse, and maintain the normal morphology of the ovary. Specifically, the SPRC can improve the number and quality of follicles in the ovary by reducing cell apoptosis, and ultimately rescue the ovarian damage caused by POI.

The invention provides an application of a hydrogen sulfide donor SPRC in improving early-onset ovarian insufficiency caused by chemotherapeutic drugs, relates to the technical field of biomedicine, and has the technical key point that the application of the hydrogen sulfide donor SPRC in preparing drugs for improving the early-onset ovarian insufficiency is provided. The application aims to solve the technical problems that the ovarian function and reproductive capacity of women are reduced, including the ovarian index is reduced, the number of follicles at all levels is reduced and the number of apoptotic cells in ovarian tissues is remarkably increased, caused by premature ovarian insufficiency at present. Specific verification experiments prove that by supplementing a hydrogen sulfide donor SPRC in a premature ovarian insufficiency mouse model, the weight and the ovarian index of the mouse can be increased, the normal form of the ovarian can be maintained, specifically, the SPRC can improve the number and the quality of follicles in the ovarian by reducing cell apoptosis, and finally ovarian injury caused by POI is rescued.

The invention relates to a foot bath powder for treating premature ovarian insufficiency and a preparation method thereof, according to a Yao medicine foot bath composition provided by the invention, through stimulation of foot meridians and acupoints, effective components of the medicine are absorbed through skin and directly reach a disease site, so that the effects of tonifying kidney and replenishing essence, conditioning Chong and Ren channels, promoting blood circulation to remove blood stasis and nourishing blood and tranquilizing are achieved; therefore, ovarian functions are improved, various symptoms caused by premature ovarian insufficiency are relieved, and the traditional Chinese medicine composition is suitable for being popularized and applied clinically and at home.

The application relates to an oral drug delivery system with a double-emulsion structure and application thereof in preparation of a medicine for treating premature ovarian insufficiency, and belongs to the technical field of biological medicines. The oral drug delivery system comprises an oil-phase solvent, MSCs conditioned medium is wrapped in the inside to form a droplet particle, and exosomes are uniformly distributed on the outer surface of the droplet particle, thereby forming a double-emulsion structure. The water-soluble MSC-CM is wrapped by a water-in-oil-in-water method to form a double-emulsion structure, so that the water-soluble protein is absorbed into the human body in an oral mode. The application has good structural stability and viscoelasticity, the particle size range is about 10-50 mu m, the contact with the intestinal epithelial cells is facilitated, meanwhile, the skeleton of the intestinal epithelial cells can be changed, the expression of the tight junction protein of the intestinal epithelial cells is lowered, the tight junction barrier of the intestinal epithelial cells is opened, and therefore the bioavailability of the MSC-CM is improved, and the role of treating POI is played.

The application relates to a traditional Chinese medicine composition for nourishing kidney and relieving depression as well as a preparation method and application thereof. The application relates to a traditional Chinese medicine composition and a preparation method and application thereof. In order to solve the problems that long-term hormone replacement therapy not only has more adverse reactions, but also has potential risks of causing endometrial lesions, thrombosis and tumors, the traditional Chinese medicine composition comprises radix codonopsis, radix ophiopogonis, taxilli herba, radix dioscoreae, ligustri fructus, anemarrhena asphodeloides, herba ecliptae, radix paeoniae alba, radix bupleuri, pericarpium citri reticulatae, fritillaria, poria cocos, semen ziziphi spinosae and schisandra chinensis. The traditional Chinese medicine composition is applied to preparation of a medicine for preventing and / or treating perimenopausal syndrome and premature ovarian failure. The application belongs to the technical field of medicines.

The invention discloses a pharmaceutical composition containing semen cuscutae, which is prepared from the following raw material medicines in parts by weight: 20 to 70 parts of semen cuscutae, 25 to 70 parts of fructus lycii, 10 to 35 parts of rhizoma dioscoreae, 0 to 20 parts of poria cocos and 1 to 20 parts of semen nelumbinis. The pharmaceutical composition can be used for preventing and / or treating ovarian reserve function decline, premature ovarian insufficiency and / or premature ovarian failure.

This specification describes a pharmaceutical composition of a melatonin receptor agonist for use in tissues outside the CNS. Also described herein are methods of using the pharmaceutical compositions described herein to improve the menopause system and to improve reproductive outcomes in polycystic ovary syndrome, endometriosis, chemotherapy-induced ovarian dysfunction, and inflammatory and metabolic diseases.

The invention discloses a preparation method and application of a medicine for preventing and treating premature ovarian failure, the medicine comprises the following components in parts by weight: 3-10 parts of eucommia ulmoides, 2-8 parts of salvia miltiorrhiza and 1-6 parts of ligusticum wallichii. The premature ovarian failure (POF) is also called ovarian insufficiency, refers to ovarian function decline, follicle-stimulating hormone level increase and estrogen level decrease of women before 40 years old, and shows secondary amenorrhea and infertility, and is often accompanied with menopausal symptoms such as sweating, insomnia, hypomnesis and the like in a night sleep process; at present, hormone replacement treatment is a main treatment method for premature ovarian failure, but the side effect is large after hormone is taken for a long time, and the probability of suffering from breast cancer and endometrial cancer can be increased; the medicine composition disclosed by the invention can be further developed into a molecular traditional Chinese medicine for preventing POF and delaying the POF process, so that the comprehensive utilization of the composition is promoted, and a new choice is provided for patients with POF.

The invention discloses a method for relieving early-onset ovarian insufficiency of mice. The method comprises the following steps: S11, selecting experimental animals: 8-week-old ICR mice which are female, 20-25g and clean; s12, grouping the mice and establishing a POI (Point of Interest) mouse model; s13, administration is carried out on the mice in different groups; s14, identifying the estrus cycle of each group of mice; according to the method for relieving the early-onset ovarian insufficiency of the mice, AS-IV can promote primordial follicle activation and follicle development of all levels by activating PI3K / AKt / mTOR signal channels and inhibit follicle atresia so as to play a role in relieving POI symptoms, and the effect of AS-IV with the medium dosage (80 mg / kg / d) is more obvious.